ReShape Lifesciences Files 8-K on Shareholder Vote Matters
Ticker: HIND · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
ReShape Lifesciences is holding a shareholder vote on August 7th. Details to follow.
AI Summary
ReShape Lifesciences Inc. filed an 8-K on August 11, 2025, reporting a submission of matters to a vote of security holders on August 7, 2025. The company, formerly known as Obalon Therapeutics Inc., is incorporated in Delaware and headquartered in San Clemente, California.
Why It Matters
This filing indicates that ReShape Lifesciences Inc. is proceeding with matters requiring shareholder approval, which could impact corporate strategy or significant transactions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an event that inherently carries high risk.
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- Obalon Therapeutics Inc. (company) — Former company name
- August 7, 2025 (date) — Date of earliest event reported
- August 11, 2025 (date) — Filing date
FAQ
What specific matters are being submitted for a vote of ReShape Lifesciences Inc. security holders?
The filing states that the report concerns the 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 7, 2025.
What is the principal executive office address for ReShape Lifesciences Inc.?
The principal executive offices are located at 18 Technology Drive, Suite 110, Irvine, CA 92618.
What was ReShape Lifesciences Inc. formerly known as?
The company was formerly known as Obalon Therapeutics Inc.
On what date was this 8-K filing submitted to the SEC?
The filing was submitted on August 11, 2025.
Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2025-08-11 16:05:51
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RSLS The Nasdaq C
Filing Documents
- tm2523158d1_8k.htm (8-K) — 30KB
- 0001104659-25-076151.txt ( ) — 191KB
- rsls-20250807.xsd (EX-101.SCH) — 3KB
- rsls-20250807_lab.xml (EX-101.LAB) — 33KB
- rsls-20250807_pre.xml (EX-101.PRE) — 22KB
- tm2523158d1_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 7, 2025, ReShape Lifesciences Inc. (the "Company") reconvened its special meeting of stockholders ("Special Meeting"), which was partially adjourned on July 24, 2025. The Special Meeting was partially adjourned solely with respect to the voting on Proposal 2, the proposal to approve the sale of substantially all of the Company's assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (the "Asset Sale"), and Proposal 3, the proposal to approve and adopt proposed amendments to the Company's Restated Certificate of Incorporation, as amended, in connection with the Company's proposed merger with Vyome Therapeutics, Inc (the "Merger"), each as described further in the Company's proxy statement for the Special Meeting filed with the Securities and Exchange Commission on June 24, 2025 (the "Proxy Statement"). The final results for Proposal 2 and Proposal 3, each as set forth in the Proxy Statement, are as follows: Proposal 2 : The Company's stockholders approved the Asset Sale, as set forth below. Votes For Votes Against Abstentions 1,273,715 26,206 2,305 Proposal 3 : The Company's stockholders approved and adopted the proposed amendments to Article VI of the Company's Restated Certificate of Incorporation, as amended, a copy of which is attached to the Proxy Statement as Annex D, which will take effect substantially concurrently with the effective time of the Merger, as set forth below. Votes For Votes Against Abstentions 1,240,191 58,555 3,480
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RESHAPE LIFESCIENCES INC. By: /s/ Paul F. Hickey Paul F. Hickey President and Chief Executive Officer Dated: August 11, 2025